Lovly et al. have identified a therapeutic synergism between inhibitors of ALK and insulin-like growth factor 1 receptor (IGF1R) by analysing the response of a patient with ALK-positive lung cancer to a treatment combination that included an IGF1R inhibitor. The authors found that the IGF1R pathway was activated in ALK inhibition-resistant cells, and that an IGF1R-specific monoclonal antibody sensitized cells to ALK inhibition.
References
Lovly, C. M. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer. Nature Med. 20, 1027–1034 (2014)
Rights and permissions
About this article
Cite this article
Villanueva, M. Insights from exceptional responders. Nat Rev Cancer 14, 647 (2014). https://doi.org/10.1038/nrc3836
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3836
